

**PRESS RELEASE**  
For immediate release



**Algorithmme Pharma Gains U.S. Footing in Baltimore,  
Through Acquisition of Clinical Pharmacology Research Unit  
Owned by BASi, Bioanalytical Systems Inc.**

**LAVAL, Thursday, July 3, 2008 — For the very first time in its history, the Laval-based firm Algorithmme Pharma, which already has many U.S. clients, has achieved its goal of locating in the U.S., through its acquisition of a new clinical research centre in Baltimore, Maryland.**

This acquisition, which is helping Algorithmme Pharma get closer to its U.S. clientele, in order to better serve this market, is the first milestone in its U.S. expansion plans. The Clinical Pharmacology Research Unit, owned by Bioanalytical Systems Inc. (NASDAQ: BASI) in Baltimore, will be operating, from now on, under the name of Algorithmme Pharma USA Inc.

“This acquisition is the first step in our U.S. expansion strategy and is part of a vast development plan to pursue our organic growth in Canada and take advantage of business opportunities that will enable us to diversify on the international scene, in both the U.S. and Europe”, stated Louis Caillé, President and Chief Executive Officer of Algorithmme Pharma.

The activities related to the new Baltimore clinic include a 46,000-square-foot work space with 120 beds (20 of which are dedicated for Intensive Monitoring Unit), divided into three separate research units, making it possible to carry out a number of studies at the same time, so that Algorithmme Pharma can increase its production capacity by over 50%. BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The Clinical Pharmacology Research Unit in Baltimore specializes in Phase I clinical trials and bioequivalence studies. Algorithmme Pharma's new clinical research centre has a core team of approximately 40 employees who will join those already working at the company's facilities in Montreal and Laval.

**About Algorithmme Pharma – As a worldwide leader in clinical research and bioanalysis, Algorithmme Pharma provides a wide range of services for bioequivalence and early stage development (Phase I) studies to the generic, pharmaceutical, and bio-technology industries. In addition to its multi-unit clinical facilities (more than 250 beds) and with its new dedicated state-of-the-art facility for Phase I clinical studies, Algorithmme Pharma offers different services including protocol designs, CTD/ICH clinical reports, data management, biostatistics, quality assurance (QA) and regulatory affairs.**

Successfully audited by US FDA, Canada’s TPD, Brazil’s ANVISA, France’s AFSSAPS, UK’s MHRA and more recently Austria’s AGES regulatory authorities, Algorithmme Pharma conducts over 250 clinical trials per year. Proud winner of Canada’s 50 Best Managed Companies, Algorithmme Pharma’s main success resides in the flexibility and commitment of its 500 + dedicated and knowledgeable employees to deliver first-class service to each Client.

**INFORMATION:**

**SOURCE:**

**PRESS RELATIONS**

**Ingrid Saumart: 514.490.0206**

**[ingrids@sympatico.ca](mailto:ingrids@sympatico.ca)**

Marius S. Brisson, President



**Mr. Louis Caillé**

President & CEO

Algorithme Pharma

[www.algopharm.com](http://www.algopharm.com)

